US Patent

US9549999 — Radiopharmaceutical composition

Formulation · Assigned to GE Healthcare Ltd · Expires 2030-03-10 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a radiopharmaceutical composition made with 99m Tc-tetrofosmin and a radioprotectant at a specific molar ratio.

USPTO Abstract

The present invention provides a 99m Tc-tetrofosmin radiopharmaceutical composition comprising tetrofosmin and a radioprotectant at a particular range of molar ratios. A kit and a multi-dose kit for the preparation of the radiopharmaceutical composition of the invention are also provided, as well as a process for the preparation of multiple unit patient doses of the radiopharmaceutical composition and a unit dose of the radiopharmaceutical composition.

Drugs covered by this patent

Patent Metadata

Patent number: US9549999
Jurisdiction: US
Classification: Formulation
Expires: 2030-03-10
Drug substance claim: No
Drug product claim: Yes
Assignee: GE Healthcare Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.